About Calistoga

Calistoga Pharmaceuticals, Inc. is the leader in developing innovative oral medicines targeting selected isoforms of the PI3 kinase pathway to improve the health of patients with cancer and inflammatory diseases.

Calistoga Pharmaceuticals has a portfolio of proprietary compounds selectively targeting the isoforms of the PI3 kinase pathway.

• CAL-101: an oral, p110δ (delta) selective PI3 kinase inhibitor under clinical evaluation in patients with hematologic malignancies.
• CAL-120: an oral, PI3 kinase inhibitor with p110δ and, p110β (beta) inhibition under preclinical evaluation for the treatment of patients with solid tumor malignancies.
• CAL-263: an oral, p110δ selective PI3 kinase inhibitor advancing toward Phase 2 for treatment of patients with inflammatory diseases.

Calistoga Pharmaceuticals is a private, venture backed company with top tier investors including Frazier Healthcare, Alta Partners, Three Arch, and Amgen Ventures. The company is led by a seasoned management team, all with experience developing successful commercialized products.

With a portfolio of isoform-select PI3K inhibitors, Calistoga Pharmaceuticals is uniquely positioned to be the first company to demonstrate the clinical benefit of these PI3 kinase inhibitors in patients with cancer and inflammatory diseases.